Enasidenib(Avatrombopag) Instructions:Uses,Dosage, Side Effects

DOPTELET is indicated for the treatment of thrombocytopenia in three distinct patient groups:

Adult patients with chronic liver disease who are scheduled to undergo a procedure.

Adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Pediatric patients 1 year of age and older with persistent or chronic ITP who have had an insufficient response to a previous treatment.

Dosage is individualized based on indication, patient age, and platelet count.

Chronic Liver Disease (Adults): A 5-day oral regimen starting 10-13 days pre-procedure. Dose is 40 mg (2 tablets) or 60 mg (3 tablets) once daily with food, based on pre-procedure platelet count.

Chronic ITP (Adults & Pediatrics ≥6 years): Initial dose is 20 mg (1 tablet) once daily with food. Dose is titrated based on weekly platelet monitoring to achieve and maintain a count ≥50×10⁹/L, not to exceed 40 mg daily. Complex weekly schedules are used for titration.

Chronic ITP (Pediatrics 1 to <6 years): Initial dose is 10 mg (contents of 1 SPRINKLE capsule) once daily mixed with soft food/liquid. Dose is titrated similarly, not to exceed 20 mg daily.

Dosage adjustments are required with concomitant use of moderate or strong dual CYP2C9 and CYP3A4 inhibitors or inducers.